Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.
The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
It also has various preclinical programs.
The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | 0.00 Increased by +100.00% | -2.42 Increased by +100.00% |
| Feb 26, 24 | -3.53 Increased by +17.72% | -3.96 Increased by +10.86% |
| Nov 9, 23 | -1.20 Increased by +77.74% | -3.11 Increased by +61.41% |
| Aug 2, 23 | -3.64 Increased by +34.88% | -2.81 Decreased by -29.54% |
| May 4, 23 | -3.34 Increased by +21.23% | -3.77 Increased by +11.41% |
| Feb 28, 23 | -4.29 Increased by +30.36% | -4.16 Decreased by -3.12% |
| Nov 9, 22 | -5.39 Decreased by -20.85% | -3.91 Decreased by -37.85% |
| Aug 8, 22 | -5.59 Decreased by -6.88% | -4.88 Decreased by -14.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 781.31 M Increased by +101.56% | 215.41 M Increased by +138.64% | Increased by +27.57% Increased by +119.17% |
| Jun 30, 23 | 595.26 M Increased by +74.27% | -381.14 M Increased by +33.30% | Decreased by -64.03% Increased by +61.73% |
| Mar 31, 23 | 447.80 M Increased by +46.04% | -348.43 M Increased by +19.77% | Decreased by -77.81% Increased by +45.06% |
| Dec 31, 22 | 380.10 M Increased by +77.63% | -445.33 M Increased by +23.96% | Decreased by -117.16% Increased by +57.19% |
| Sep 30, 22 | 387.63 M Increased by +87.77% | -557.56 M Decreased by -34.72% | Decreased by -143.84% Increased by +28.25% |
| Jun 30, 22 | 341.57 M Increased by +127.73% | -571.45 M Decreased by -18.97% | Decreased by -167.30% Increased by +47.76% |
| Mar 31, 22 | 306.63 M Decreased by -49.39% | -434.27 M Decreased by -753.09% | Decreased by -141.63% Decreased by -1.39 K% |
| Dec 31, 21 | 213.98 M Increased by +113.77% | -585.65 M Decreased by -23.88% | Decreased by -273.70% Increased by +42.05% |